STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
Enjoy, and see you soon… Artificial intelligence has sped early-stage drug development work at some of the world’s largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them into the clinic, Reuters explains.
- The disclosure was made by the House Select Committee on China, which last June opened investigations into five companies — Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb — over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites in sensitive regions of the country.
- As noted previously, this remains a fine time to enjoy the great outdoors — perhaps a drive in the country is in order or a long walk by a lake or ocean.
- Continue to STAT+ to read the full story….
A few of the largest pharmaceutical companies have told a Congressional committee that they do not plan to start new clinical trial sites in the Xinjiang region of China or at hospitals affiliated with the Chinese military, STAT writes.
- We plan to catch up on our reading, escort Mrs.
- They are now using the technology for designing molecules, sorting out the most promising ones, and identifying safety risks.
- We also plan to hold another listening party, where the rotation will likely include this, this, this, this and this.
- Speaking of holidays, we will be off next week but never fear, a team of pinch hitters will be on hand.
- Meanwhile, whatever you do over the next 10 days or so, we hope you do something smashing.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →